生存5年以上多发性骨髓瘤患者43例临床观察  

Clinical analysis of 43 cases with multiple myeloma surviving more than 5 years

作　　者：申曼[1] 张佳佳[1] 陈世伦[1] 李新[1] 黄仲夏[1] 钟玉萍[1] 安娜[1] 胡影[1] 詹晓凯[1] 

机构地区：[1]首都医科大学附属北京朝阳医院京西院区血液科北京市多发性骨髓瘤医疗研究中心,100043

出　　处：《白血病．淋巴瘤》2015年第10期587-590,594,共5页Journal of Leukemia & Lymphoma

摘　　要：目的 分析生存期大于5年多发性骨髓瘤（MM）患者的临床特点及其与预后的关系.方法 收集2005年9月至2009年9月确诊的43例生存期大于5年MM患者的临床资料,总结患者临床特征、实验室指标和治疗情况,并分析其与生存期的关系.结果 43例患者中,男性23例,女性20例,中位年龄59岁,中位生存期80个月,不同的国际ISS分期对应的中位生存期分别为Ⅰ期120个月,Ⅱ期93个月,Ⅲ期80个月.所有患者均接受过硼替佐米化疗;复发患者接受了含硼替佐米方案、DECP方案、来那度胺、三氧化二砷及脂质体多柔比星等药物治疗.化疗中位疗程数25个（15 ～ 46个）.结论 MM的预后不仅与肿瘤负荷、宿主因素及肿瘤生物学特征等有关,还与治疗方案及对治疗的反应密切相关.硼替佐米、来那度胺等新型靶向药物对初诊及复发难治MM均有较好疗效.Objective To analysis the relationship of clinical characteristics and prognosis of multiple myeloma （MM） patients surviving more than 5 years.Methods The clinical features, laboratory parameters and treatment programs of 43 cases diagnosed MM from September 2005 to September 2009 were collected to analyze the influence factors related to survival.Results 43 patients included 23 male cases, 20 female cases, with a median age of 59 years old （38-76 years old）, and the median survival time was 80 months （60-124 months）.Different ISS stage corresponded to different median survival phase, phase Ⅰ 120 months, phase Ⅱ 93 months, phase Ⅲ 80 months.The 43 patients had received the median of 25 cycles （15-46 cycles） of chemotherapy, all of them had received chemotherapy of bortezomib.The relapsed MM patients had received chemotherapy with bortezomib mainly, DECP, lenalidomide, arsenic trioxide and pcgylated liposomal doxorubicin.Conclusions Besides tumor burden, host factors and tumor biology, the prognosis of MM correlates with the treatment modality and response to therapy.The new target drugs such as bortezomib and lenalidomide have good curative effect on either newly diagnosed or relapsed and refractory MM.

关 键 词：多发性骨髓瘤 长生存 预后 

分 类 号：R733.3[医药卫生—肿瘤]